Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review.
COVID-19
health policy
public health
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
02 12 2021
02 12 2021
Historique:
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
15
12
2021
Statut:
epublish
Résumé
The four SARS-CoV-2 variants of concern (VOC; Alpha, Beta, Gamma and Delta) identified by May 2021 are highly transmissible, yet little is known about their impact on public health measures. We aimed to synthesise evidence related to public health measures and VOC. A rapid scoping review. On 11 May 2021, seven databases (MEDLINE, Embase, the Cochrane Database of Systematic Reviews, Central Register of Controlled Trials, Epistemonikos' L-OVE on COVID-19, medRxiv, bioRxiv) were searched for terms related to VOC, public health measures, transmission and health systems. No limit was placed on date of publication. Studies were included if they reported on any of the four VOCs and public health measures, and were available in English. Only studies reporting on data collected after October 2020, when the first VOC was reported, were included. Titles, abstracts and full-text articles were screened by two independent reviewers. Data extraction was completed by two independent reviewers using a standardised form. Data synthesis and reporting followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines. Of the 37 included studies, the majority assessed the impact of Alpha (n=32) and were conducted in Europe (n=12) or the UK (n=9). Most were modelling studies (n=28) and preprints (n=28). The majority of studies reported on infection control measures (n=17), followed by modifying approaches to vaccines (n=13), physical distancing (n=6) and either mask wearing, testing or hand washing (n=2). Findings suggest an accelerated vaccine rollout is needed to mitigate the spread of VOC. The increased severity of VOC requires proactive public health measures to control their spread. Further research is needed to strengthen the evidence for continued implementation of public health measures in conjunction with vaccine rollout. With no studies reporting on Delta, there is a need for further research on this and other emerging VOC on public health measures.
Identifiants
pubmed: 34857582
pii: bmjopen-2021-055781
doi: 10.1136/bmjopen-2021-055781
pmc: PMC8640198
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e055781Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Epidemics. 2022 Mar;38:100535
pubmed: 34923396
Nature. 2021 Aug;596(7872):417-422
pubmed: 34192737
Isr J Health Policy Res. 2021 Feb 19;10(1):16
pubmed: 33608023
Syst Rev. 2012 Feb 10;1:10
pubmed: 22587960
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
Econ Disaster Clim Chang. 2021;5(2):177-201
pubmed: 33997600
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
Commun Med (Lond). 2022 Nov 19;2(1):146
pubmed: 36402924
J Clin Virol Plus. 2021 Jun;1(1):100013
pubmed: 35262001
PLoS One. 2016 Jan 25;11(1):e0147601
pubmed: 26808317
Euro Surveill. 2021 Apr;26(15):
pubmed: 33860748
Can Commun Dis Rep. 2019 Jan 03;45(1):12-23
pubmed: 31015816
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Clin Infect Dis. 2022 Mar 1;74(4):703-706
pubmed: 34105720
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924
pubmed: 33332292
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Euro Surveill. 2021 Mar;26(10):
pubmed: 33706862
Cureus. 2021 Mar 11;13(3):e13819
pubmed: 33728228
Nat Commun. 2022 Jan 27;13(1):554
pubmed: 35087051
Lancet. 2020 Apr 25;395(10233):1382-1393
pubmed: 32277878
Lancet Public Health. 2021 May;6(5):e335-e345
pubmed: 33857453
Cell Rep Med. 2021 May 18;2(5):100264
pubmed: 33899031
Sci Rep. 2022 May 23;12(1):8630
pubmed: 35606393
Int J Evid Based Healthc. 2015 Sep;13(3):141-6
pubmed: 26134548
Arch Comput Methods Eng. 2021;28(6):4225-4236
pubmed: 34456557
EClinicalMedicine. 2021 Aug;38:101036
pubmed: 34308302
EClinicalMedicine. 2021 May;35:100865
pubmed: 33937735
Mol Biol Rep. 2021 Nov;48(11):7243-7249
pubmed: 34613565
Nat Med. 2021 Jun;27(6):993-998
pubmed: 33864052
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
BMC Infect Dis. 2022 Apr 4;22(1):333
pubmed: 35379190
Sci Rep. 2022 May 6;12(1):7493
pubmed: 35523832
J Infect. 2021 Jul;83(1):e26-e28
pubmed: 33933529
Clin Infect Dis. 2022 Apr 9;74(7):1208-1219
pubmed: 34216472
Lancet Infect Dis. 2021 Jun;21(6):793-802
pubmed: 33743847
J Infect Dis. 2021 Aug 2;224(3):420-424
pubmed: 33993274
BMJ. 2020 Dec 2;371:m4714
pubmed: 33268330
BMJ Open. 2021 Dec 2;11(12):e055781
pubmed: 34857582